Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

BACKGROUND AND PURPOSE—: In the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients), empagliflozin added to standard of care in patients with type 2 diabetes mellitus and high cardiovascular risk reduced the risk of 3-point major adverse car...

Descripción completa

Detalles Bibliográficos
Autores principales: Zinman, Bernard, Inzucchi, Silvio E., Lachin, John M., Wanner, Christoph, Fitchett, David, Kohler, Sven, Mattheus, Michaela, Woerle, Hans J., Broedl, Uli C., Johansen, Odd Erik, Albers, Gregory W., Diener, Hans Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Original Contributions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404404/
https://www.ncbi.nlm.nih.gov/pubmed/28386035
http://dx.doi.org/10.1161/STROKEAHA.116.015756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404404/
https://www.ncbi.nlm.nih.gov/pubmed/28386035
http://dx.doi.org/10.1161/STROKEAHA.116.015756

Ejemplares similares